Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome

​Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene therapy targeting Pitt Hopkins syndrome.

The post Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.